{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T07:49:36Z","timestamp":1774511376324,"version":"3.50.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,25]]},"DOI":"10.7759\/cureus.105864","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T06:00:07Z","timestamp":1774504807000},"source":"Crossref","is-referenced-by-count":0,"title":["Management Dilemma: Myeloperoxidase (MPO)-Positive Vasculitis in a Patient With Metastatic Malignant Melanoma"],"prefix":"10.7759","author":[{"given":"Aarush","family":"Sajjad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashwin","family":"Manivannan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1803537","article-title":"Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis","volume":"382","author":"Walsh M","year":"2020","unstructured":"Walsh M, Merkel PA, Peh CA, et al.. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med. 2020, 382:622-31. 10.1056\/NEJMoa1803537","journal-title":"N Engl J Med"},{"key":"ref2","article-title":"ANCA-associated vasculitis","author":"Qasim A","year":"2024","unstructured":"Qasim A, Patel JB. ANCA-associated vasculitis. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2024."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221794","article-title":"2022 American College of Rheumatology\/European Alliance of Associations for Rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis","volume":"81","author":"Grayson PC","year":"2022","unstructured":"Grayson PC, Ponte C, Suppiah R, et al.. 2022 American College of Rheumatology\/European Alliance of Associations for Rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis. Ann Rheum Dis. 2022, 81:309-14. 10.1136\/annrheumdis-2021-221794","journal-title":"Ann Rheum Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223764","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","volume":"83","author":"Hellmich B","year":"2024","unstructured":"Hellmich B, Sanchez-Alamo B, Schirmer JH, et al.. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis. 2024, 83:30-47. 10.1136\/ard-2022-223764","journal-title":"Ann Rheum Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12185996","article-title":"Eosinophilic granulomatosis with polyangiitis: latest findings and updated treatment recommendations","volume":"12","author":"Watanabe R","year":"2023","unstructured":"Watanabe R, Hashimoto M. Eosinophilic granulomatosis with polyangiitis: latest findings and updated treatment recommendations. J Clin Med. 2023, 12:5996. 10.3390\/jcm12185996","journal-title":"J Clin Med"},{"key":"ref6","doi-asserted-by":"crossref","DOI":"10.1038\/s41584-018-0074-9","article-title":"Rheumatic immune-related adverse events from cancer immunotherapy","volume":"14","author":"Calabrese LH","year":"2018","unstructured":"Calabrese LH, Calabrese C, Cappelli LC. Rheumatic immune-related adverse events from cancer immunotherapy. Nat Rev Rheumatol. 2018, 14:569-79.","journal-title":"Nat Rev Rheumatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/art.41068","article-title":"Safety and efficacy of immune checkpoint inhibitors in patients with preexisting autoimmune disease: a nationwide, multicenter cohort study","volume":"71","author":"Tison A","year":"2019","unstructured":"Tison A, Qu\u00e9r\u00e9 G, Misery L, et al.. Safety and efficacy of immune checkpoint inhibitors in patients with preexisting autoimmune disease: a nationwide, multicenter cohort study. Arthritis Rheumatol. 2019, 71:2100-11. 10.1002\/art.41068","journal-title":"Arthritis Rheumatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-018-4177-0","article-title":"Vasculitis associated with immune checkpoint inhibitors-a systematic review","volume":"37","author":"Daxini A","year":"2018","unstructured":"Daxini A, Cronin K, Sreih AG. Vasculitis associated with immune checkpoint inhibitors-a systematic review. Clin Rheumatol. 2018, 37:2579-84. 10.1007\/s10067-018-4177-0","journal-title":"Clin Rheumatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102596","article-title":"Risk of scleroderma according to the type of immune checkpoint inhibitors","volume":"19","author":"Terrier B","year":"2020","unstructured":"Terrier B, Humbert S, Preta LH, et al.. Risk of scleroderma according to the type of immune checkpoint inhibitors. Autoimmun Rev. 2020, 19:102596. 10.1016\/j.autrev.2020.102596","journal-title":"Autoimmun Rev"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0478-8","article-title":"Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience","volume":"7","author":"Mamlouk O","year":"2019","unstructured":"Mamlouk O, Selamet U, Machado S, et al.. Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience. J Immunother Cancer. 2019, 7:2. 10.1186\/s40425-018-0478-8","journal-title":"J Immunother Cancer"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/life15050756","article-title":"Current understanding of the pathogenesis of anca-associated vasculitis and novel treatment options targeting complement activation","volume":"15","author":"Drouzas K","year":"2025","unstructured":"Drouzas K, Kalogeropoulos P, Liapis G, Lionaki S. Current understanding of the pathogenesis of anca-associated vasculitis and novel treatment options targeting complement activation. Life (Basel). 2025, 15:756. 10.3390\/life15050756","journal-title":"Life (Basel)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaf240","article-title":"The 2025 British Society for Rheumatology management recommendations for ANCA-associated vasculitis","volume":"64","author":"Biddle K","year":"2025","unstructured":"Biddle K, Jade J, Wilson-Morkeh H, et al.. The 2025 British Society for Rheumatology management recommendations for ANCA-associated vasculitis. Rheumatology (Oxford). 2025, 64:4470-94. 10.1093\/rheumatology\/keaf240","journal-title":"Rheumatology (Oxford)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler ME","year":"2017","unstructured":"Wechsler ME, Akuthota P, Jayne D, et al.. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med. 2017, 376:1921-32. 10.1056\/NEJMoa1702079","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2311155","article-title":"Benralizumab versus mepolizumab for eosinophilic granulomatosis with polyangiitis","volume":"390","author":"Wechsler ME","year":"2024","unstructured":"Wechsler ME, Nair P, Terrier B, et al.. Benralizumab versus mepolizumab for eosinophilic granulomatosis with polyangiitis. N Engl J Med. 2024, 390:911-21. 10.1056\/NEJMoa2311155","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s41927-025-00569-w","article-title":"Efficacy and safety of avacopan in the treatment of ANCA-associated vasculitis: a systematic review and meta-analysis","volume":"9","author":"Aldhuaina K","year":"2025","unstructured":"Aldhuaina K, Alghanim K. Efficacy and safety of avacopan in the treatment of ANCA-associated vasculitis: a systematic review and meta-analysis. BMC Rheumatol. 2025, 9:115. 10.1186\/s41927-025-00569-w","journal-title":"BMC Rheumatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/459345-management-dilemma-myeloperoxidase-mpo-positive-vasculitis-in-a-patient-with-metastatic-malignant-melanoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T06:00:07Z","timestamp":1774504807000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/459345-management-dilemma-myeloperoxidase-mpo-positive-vasculitis-in-a-patient-with-metastatic-malignant-melanoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.105864","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,25]]}}}